An interventional study of Willem™ platform ECG assessment in Heart Failure and Cardiovascular Risk Factors, sponsored by Idoven 1903 S.L.. Recruiting at 5 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Idoven 1903 S.L. · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.
Among the 342 studies in Heart Failure with a site in Spain, this one is the 39th largest by planned enrollment of the 263 interventional ones that give a count, is one of 31 that started in 2025, is one of 119 with no phase, reaches primary completion later than 40 of the 98 other live ones, and was the 312th registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:
AnaCardio AB · Sites in Spain, United States, Bulgaria and 5 more countries
Ages 18–85
Carolina Ortiz Cortes · Sites in Spain
Ages 18+ · Women only
AstraZeneca · Sites in Spain, United States, Argentina and 29 more countries
Ages 18+
AstraZeneca · Sites in Spain, United States, Germany and 2 more countries
Ages 18+
Biotronik SE & Co. KG · Sites in Spain, Austria, Czechia and 4 more countries
Ages 18–99
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 42 · Phase 3 78 · Phase 4 24
First in 1983; this study’s year is marked. 31 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,968 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 294 across the 263 interventional studies, 500 across the 78 observational. Of the 213 that completed or were terminated, 86 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
190 of 342 have an industry lead sponsor. The 10 most frequent:
Idoven 1903 S.L. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Idoven 1903 S.L. has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
31 of the studies in Heart Failure with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07008365Phase 3Instituto de Investigación Sanitaria AragónThe Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure | 2026-11-30 |
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT06712030Phase 3Puerta de Hierro University HospitalEffect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction | 2027-04 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 31 to your calendar (.ics) → With an account.
Among the 342 studies in Heart Failure with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The DECISION trial aims to evaluate the efficacy of an artificial intelligence (AI)-powered system, Willem™, for improving the detection of heart failure (HF) in primary care settings by interpreting electrocardiograms (ECGs). The study seeks to answer whether AI-assisted ECG interpretation enhances diagnostic accuracy and clinical outcomes compared to standard ECG evaluation in patients with suspected HF or those at high risk.
This multicenter, pragmatic, randomized clinical trial involves two groups: patients receiving AI-assisted ECG analysis and those undergoing standard ECG evaluation. The study's primary analysis will compare the diagnostic performance of AI-assisted ECG versus standard ECG using sensitivity, specificity, and predictive value metrics. Secondary analyses will evaluate healthcare resource utilization, clinical outcomes, and usability feedback from healthcare providers. Results will inform the potential integration of AI-assisted ECG in routine primary care workflows for earlier HF detection and better resource allocation.
Heart failure (HF) is a prevalent and underdiagnosed condition with high morbidity and mortality. Up to 50% of HF cases remain undetected, often due to subtle or absent symptoms in early stages. Early diagnosis is critical to improving outcomes, reducing hospitalizations, and alleviating healthcare costs. While ECGs are a cornerstone in HF diagnosis, their interpretation in primary care can be challenging, leading to diagnostic delays.
Artificial intelligence (AI) has emerged as a promising tool to support clinicians by enhancing ECG interpretation. In this regard, the DECISION trial evaluates the Willem™ platform, an AI-powered decision-support system, to improve HF detection. Willem™ uses a proprietary database to analyze ECGs, identifying over 80 cardiac patterns with high accuracy.
This study hypothesizes that AI-assisted ECG improves HF detection compared to standard ECG interpretation. Therefore, the main goal of the DECISION trial is to assess the diagnostic performance of AI-assisted ECG in detecting structural and functional cardiac abnormalities indicative of HF.
This multicenter, randomized trial includes primary care centers (PCCs) in Spain and Sweden, randomized into two groups: an intervention group using AI-assisted ECG and a control group using standard ECG. AI outputs will be available for physicians in the intervention group as supplementary information during decision making.
Primary outcomes focus on the accuracy of HF detection confirmed by transthoracic echocardiograms (TTE). Secondary outcomes include healthcare resource utilization, clinical outcomes, and physician satisfaction. The results will inform whether AI can be integrated into primary care workflows to optimize HF diagnosis and management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with Suspected HF (Group S):
Patients at Risk of Heart Failure due to the presence of cardiovascular (Group R):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AI-assisted ECG analysis via the Willem™ platform
Device: Willem™ platform ECG assessment
Standard ECG assessment
AI-assisted ECG analysis via the Willem™ platform
Device performance in patients with suspected Heart Failure
To compare the diagnostic performance of clinicians using a decision-aid system based on AI-assisted ECG vs. standard ECG in patients with suspected Heart Failure (symptoms and/or signs of Heart Failure) in the primary care setting analyzing the frequency of patients without cardiac pattern alterations in the ECG, ending up with diagnosis of absence of HF (using the NT-proBNP for stratification and eventually echocardiography when needed) 7 days after screening with the cardiology service.
Time frame: After performing the transthoracic echocardiography (TTE) in Visit 3 (7 days after screening)
Device performance in patients at cardiovascular risk but without Heart Failure symptoms
To compare the diagnostic performance of clinicians using a decision-aid system based on AI-assisted ECG vs. standard ECG in patients at risk but without Heart Failure symptoms in the primary care setting analyzing the frequency of patients with cardiac pattern alterations in the ECG, ending up with a diagnosis of HF (using the NT-proBNP for stratification and eventually echocardiography when needed) 7 days after screening with the cardiology service.
Time frame: After performing the transthoracic echocardiography (TTE) in Visit 3 (7 days after screening)
Device performance at 6 months after ECG
To compare the clinical performance of a decision-aid system based on AI-assisted ECG vs standard ECG, in patients with symptoms and patients at risk of Heart Failure in the primary care setting analyzing the frequency of patients with cardiac pattern alterations in the ECG, ending up with diagnosis of HF (using the NT-proBNP for stratification and eventually echocardiography when needed) 6 months after screening with the cardiology service.
Time frame: Six months after the ECG was performed
Plan to share: Yes — De-identified Individual Participant Data (IPD) that underlies the results reported in the publication will be shared after publications of primary results upon request of investigators whose proposed research has received EC/IRB approval and after data use agreement.
Supporting information: Study protocol
Time frame: From the time of publication and for 5 years thereafter.
Access criteria: Upon request of investigators whose proposed research has received EC/IRB approval and after data use agreement.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 20 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Mar 2027 and completion Mar 2027 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idoven 1903 S.L.